U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C12H14N2O6
Molecular Weight 282.2494
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of NETIVUDINE

SMILES

CC#CC1=CN([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)C(=O)NC1=O

InChI

InChIKey=QLOCVMVCRJOTTM-SDNRWEOFSA-N
InChI=1S/C12H14N2O6/c1-2-3-6-4-14(12(19)13-10(6)18)11-9(17)8(16)7(5-15)20-11/h4,7-9,11,15-17H,5H2,1H3,(H,13,18,19)/t7-,8-,9+,11-/m1/s1

HIDE SMILES / InChI

Molecular Formula C12H14N2O6
Molecular Weight 282.2494
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Netivudine [882C, 882C87, BW 882, Py-araU, Zonavir®] is an orally active thymidine analogue which was being investigated as a treatment for herpes zoster virus infections. Netivudine is a nucleoside analog with potent, specific activity against varicella-zoster virus. It is approximately seven times as potent as acyclovir with an in vitro 50% inhibitory concentration of 1 to 2 uM.

Originator

Approval Year

PubMed

Sample Use Guides

In Vivo Use Guide
Three groups of eight elderly volunteers received 400 or 800 mg netivudine or placebo once daily for 8 days.
Route of Administration: Oral
In Vitro Use Guide
The IC50 of Netivudine (882C87) against VZV ranges from 0.6 to 3.8 uM.
Substance Class Chemical
Record UNII
F7K51T0Q1W
Record Status Validated (UNII)
Record Version